=Progenics Pharma (PGNX) reported earnings on Wed 9 Aug 2017 (b/o)

Progenics Pharma misses by $0.03, misses on revs

• Reports Q2 (Jun) loss of $0.24 per share, $0.03 worse than the Capital IQ Consensus of ($0.21); revenues fell 67.3% year/year to $2.77 mln vs the $3.34 mln Capital IQ Consensus. 
• AZEDRA NDA Expected to be Submitted August 2017: Progenics expects to complete the rolling submission of the NDA for AZEDRA in patients with malignant and/or recurrent pheochromocytoma to the FDA in August 2017.